Indonesia vs Syrian Arab Republic: Access to anti-retroviral drugs, female
Indonesia
36.0%
in 2024
Syrian Arab Republic
41.0%
in 2024
Indonesia rank
130th
Syrian Arab Republic rank
127th
Access to anti-retroviral drugs, female over time
- Indonesia
- Syrian Arab Republic
How they compare
Syrian Arab Republic currently reports 41.0% against 36.0% in Indonesia, a difference of 5.0%.
That makes Syrian Arab Republic's figure about 1.1 times Indonesia's.
Across all 25 years both countries report, Syrian Arab Republic has been ahead every year.
Indonesia ranks 130th and Syrian Arab Republic ranks 127th of 141 countries.
Syrian Arab Republic has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Indonesia | Syrian Arab Republic | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.3% | 5.4% | 4.1% | Syrian Arab Republic |
| 2010s | 12.9% | 26.9% | 14.0% | Syrian Arab Republic |
| 2020s | 28.8% | 41.4% | 12.6% | Syrian Arab Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Indonesia or Syrian Arab Republic?
- Syrian Arab Republic, at 41.0% against 36.0% in Indonesia as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Indonesia and Syrian Arab Republic?
- 5.0%, with Syrian Arab Republic ahead.
- How many years of comparable data are there for Indonesia and Syrian Arab Republic?
- 25 years are reported by both, from 2000 to 2024.
- How do Indonesia and Syrian Arab Republic rank globally for access to anti-retroviral drugs, female?
- Indonesia ranks 130th and Syrian Arab Republic ranks 127th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.